Managed Print & Photocopiers for Life Sciences, Biotech & Pharma
Drug discovery, biotech research and clinical-trial operations run on documentation as much as they run on data — trial protocols, batch records, regulatory submissions, IP-bearing patent material, training records and audit trails. The print and scan environment that supports all of this is rarely thought about until an MHRA or sponsor audit asks for evidence of how it’s controlled.
The sector at a glance
The UK life sciences industry is a global powerhouse and one of the largest contributors to the UK economy. Pharmaceutical manufacturers, biotech research firms, contract research organisations, medical-device producers, diagnostics specialists and clinical-trial operators together generated an estimated £146.9 billion in turnover in 2023/24, supported by approximately 6,170 businesses and a workforce of more than 359,600 people[1]. The pharmaceutical sub-sector alone invests around £9.3 billion a year in UK research and development — roughly £1 in every £6 of all private-sector R&D in the UK[2].
Document workflows in this environment carry an unusual combination of obligations. Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) all require controlled, attributable, traceable documentation. The MHRA, EMA and FDA all expect to see audit trails of how regulated documents were produced, signed and stored. Clinical-trial protocols, investigator brochures, batch records, deviation reports and patent applications are commercially valuable IP and personally sensitive data simultaneously. Training records, GxP procedures and SOPs run alongside ordinary commercial, finance and HR document handling on the same physical estate.
Regulatory inspections, sponsor audits and quality-management reviews increasingly bring print and scan devices into scope. Multifunction devices that store unencrypted job data, allow uncontrolled release in shared zones, or have no audit log of activity are a finding waiting to happen — and yet they remain extremely common, because print has historically been managed separately from IT and the quality function.
Challenges we see in the sector
Trial protocols, IP and patient data on shared output trays
Clinical operations, regulatory affairs, R&D and medical-affairs teams print high-stakes documents every day — trial protocols, investigator brochures, patent material, regulatory submissions, adverse-event reports. Documents containing commercially valuable IP and personally identifiable patient data routinely end up sitting on shared output trays in busy office environments. Under UK GDPR and the Data Protection Act 2018 this is a reportable breach risk; under MHRA and sponsor expectations of document control, it is also a quality finding waiting to happen.
GxP document control and audit-trail expectations
Good Laboratory, Manufacturing and Clinical Practice all require that regulated documents are produced, copied, scanned and stored under controlled conditions with attributable, traceable evidence of who did what, when. MHRA inspectors, sponsor auditors and internal QA functions expect to see that print and scan activity on regulated documents is logged and reviewable. Devices that allow uncontrolled, anonymous release and store no audit log produce a gap that is increasingly being challenged at inspection.
R&D, lab, clinical and admin print needs collide on the same estate
Life-sciences sites typically combine R&D laboratories, manufacturing or formulation areas, clinical-trial operations and corporate functions on the same physical campus. Print needs are very different across those zones — high-volume admin output, robust label printing in lab and warehouse environments, regulated document production in clinical and QA, premium-quality colour for investor and bid material. A one-size-fits-all device fleet either over-specifies the office or under-specifies the lab, and neither result is acceptable.
Multi-site research, manufacturing and clinical-operations networks
Pharma and biotech businesses operate across networks of UK research sites, contract-manufacturing facilities and clinical-trial operations centres — sometimes integrated with overseas affiliates and CROs. Print estates have grown organically across these very different environments, with each site running its own contracts and devices. Group quality, IT and finance functions have no consistent baseline to enforce and no consolidated visibility of device populations, contracts or compliance posture.
Patent and IP material on devices with no encryption or audit log
Patent applications, formulation records, process know-how and unpublished clinical-trial data are some of the most commercially valuable documents that exist in any sector. When the MFDs handling them have no encrypted hard drive, no automatic data overwrite, and no audit log of activity, the IP exposure is significant — and not infrequently flagged in due-diligence reviews ahead of investment, partnership or M&A activity.
Scan-to-eTMF, LIMS and document-management workflows are often manual
Modern life-sciences operations rely on electronic Trial Master Files (eTMF), Laboratory Information Management Systems (LIMS), electronic Document Management Systems (eDMS) and validated quality-management platforms. Yet documents that originate on paper — signed consent forms, lab notebook pages, source-data records, deviation reports — are frequently scanned on consumer-grade devices and emailed to a colleague to upload manually. The integrity, indexing and audit-trail risks of that manual handover are well understood and avoidable.
How we help
Authenticated secure print release for trial protocols, IP and patient data
Depending on the model, licences and configuration, our MFDs can integrate with PIN, ID badge, smartcard and mobile authentication, with role-based access to functions and per-user audit logs of print, scan and copy activity. Trial protocols, investigator brochures, patent material and patient-identifying documents can then be held for release by the named authorised user rather than left on shared output trays, and produce the kind of attributable, traceable evidence that GxP document control and UK GDPR accountability obligations expect.
Security controls matched to the selected configuration
Security controls are available depending on the device and configuration selected. These can include encrypted storage, automatic data overwrite, user authentication, secure print release and audit logging. Some controls require additional licences, accessories, PaperCut or configuration and are included only where stated in the quotation.
Scan-to-eTMF, LIMS and DMS workflows that respect document control
Scan directly from the MFD into your eTMF, LIMS, eDMS or quality-management platform — with OCR applied, indexing metadata captured at the device, and the resulting document deposited automatically against the correct study, batch or sample record. Manual rescan-and-email handovers disappear; document integrity is maintained from the point of capture; audit-trail evidence is produced as a by-product of the workflow rather than reconstructed under audit pressure.
Right-sized devices for lab, clinical, manufacturing and admin zones
A single managed estate, but with the right device specified for the right zone — high-volume admin MFDs in corporate areas, robust devices in lab and warehouse environments, premium colour MFDs for investor, regulatory and bid material. One contract, one accountable provider, but a fleet that reflects how each part of a life-sciences business actually operates rather than forcing every team onto a single compromise device.
Multi-site managed-print contract for pharma and biotech networks
A consolidated managed-print contract across every UK site — research, manufacturing, clinical operations, corporate — with one device standard, one service-level agreement, one consolidated set of usage and security reporting, and one accountable provider. Group quality gets a consistent baseline; group IT gets a fleet they can patch, monitor and audit centrally; group finance gets a single accurate cost picture rather than a patchwork of site-level contracts and consumable bills.
Audit-ready security and usage reporting
Per-user, per-device, per-site reporting on print, scan and copy activity, with retention configured to match your QA and regulatory audit cycle. MHRA inspections, sponsor audits, internal QA reviews and customer due-diligence questions about device activity are answered from reporting data rather than reconstructed manually. For life-sciences businesses where document control and traceability are regulatory expectations, this is exactly the kind of evidence base that inspectors expect to see.
What this looks like in practice
Document control that holds up under audit
Life-sciences businesses that bring their MFDs into the same controlled-document baseline as the rest of their quality system — encrypted storage, authenticated release, full audit logs, automatic data overwrite, scan-to-eTMF/LIMS integration — consistently report that print stops being an MHRA, sponsor or internal-QA audit blocker and starts being part of the evidence base. Findings against the print estate become rare; evidence requests are answered from log data; the quality function gets the same visibility of MFD activity as it does of any other GxP-relevant system.
Multi-site networks under one accountable contract
The Royal College of Surgeons of England rebuilt its print infrastructure in record time on Toshiba to support a 30,000-strong professional membership across training, education and assessment. Qualsafe, the UK’s largest provider of regulated training materials — serving over 8 million learners through 2,500+ organisations including NHS Trusts, councils and universities — addresses warehouse inefficiency and excessive consumable costs through a managed Toshiba estate. CeraCare, a tech-enabled multi-site care operator, halved its fleet and reset its print costs through consolidation. The pattern across regulated, multi-site, document-intensive businesses is consistent: a single accountable contract delivers what fragmented site-level arrangements never could.
IP and patient-data protection that meets the standard the rest of IT meets
Patent material, formulation records, unpublished clinical data and patient-identifying documents handled on encrypted, authenticated, audited MFDs are protected to the same standard as the rest of a serious life-sciences IT estate — rather than being the weak link in an otherwise credentialed environment. For businesses approaching investment, partnership, M&A or regulatory inspection, that consistency materially reduces exposure and shortens the due-diligence conversation.
What to look for in a print partner
- Authenticated secure print release for trial protocols, IP, patent material and patient-identifying documents
- Security controls matched to the device and configuration, with required licences, accessories, PaperCut or setup stated in the quotation
- Audit logging of print, scan and copy activity that supports GxP document control and MHRA/sponsor inspection evidence
- Scan-to-eTMF, LIMS and eDMS integration with metadata captured at the device
- Right-sized devices for lab, clinical, manufacturing and admin zones under one fleet contract
- Multi-site managed-print contract across research, manufacturing, clinical and corporate sites
- Per-user, per-device, per-site reporting that supports both internal QA and external regulatory inspection
- Experience working with regulated environments and the document-control expectations they carry
The bottom line
In life sciences, biotech and pharma, the print and scan estate is part of the document-control system that GxP, MHRA, sponsors and investors expect to see. Authenticated release, encrypted storage, full audit trails, scan-to-eTMF/LIMS integration and consolidated multi-site management are the baseline that any serious operator should be able to evidence — and the print estate is one of the easiest places to close a real, recurring compliance gap.
All UK Copiers works with pharma manufacturers, biotech research firms, CROs, medical-device companies and regulated-training providers across the UK to deliver managed-print environments that meet that baseline — with the multi-site consolidation, the audit-ready reporting and the IP and patient-data protection that the sector demands.
Sources: [1] Office for Life Sciences — Bioscience and health technology sector statistics 2023 to 2024, [2] ABPI — Facts, figures and industry data 2024/25, [3] ABPI — UK industry clinical trials: Translating actions into impact (December 2025)
Statistics cited above are drawn from the sources listed. Illustrative examples and ranges presented elsewhere on this page reflect our operational experience delivering managed print services to UK life-sciences, biotech and pharma businesses.
Is your print estate part of your document-control system — or a gap waiting to be found at audit?
Whether you’re preparing for an MHRA inspection, a sponsor audit, a partnership due-diligence or simply ready to consolidate a multi-site research and manufacturing estate, talk to us — we work with life-sciences, biotech and pharma businesses across the UK and understand what regulated document control demands.